RxDoctor Payments Data

Roberto Perez Gutierrez, MD

Cardiovascular Disease · Rio Piedras, PRNPI 1225042393

Payments from drug & device makers

$4,210in general payments, 2019–2025

Across 70 payments — averaging $60.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$772
  • Boehringer Ingelheim$604
  • Abbott$544
  • Amgen$516
  • Johnson & Johnson$482
  • Medtronic$277
  • plus $1K from 6 others

What the payments were for

  • Food & beverage$4,204100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,210 in reported general payments places this provider in the 55th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$11,640
Medicare patients
35
Services billed
153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis16$499,796
EliquisApixaban278$339,030
XareltoRivaroxaban123$157,302
FarxigaDapagliflozin Propanediol110$98,648
JardianceEmpagliflozin49$68,048
JanuviaSitagliptin Phosphate25$35,204
Repatha SureclickEvolocumab26$26,197
EntrestoSacubitril/Valsartan19$23,804
Atorvastatin Calcium1,400$21,848
Repatha PushtronexEvolocumab23$19,933
TradjentaLinagliptin18$18,426
Janumet XrSitagliptin Phos/Metformin Hcl12$16,886
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide482$12,187
Metoprolol Succinate554$11,774
Diltiazem 24hr Er (Cd)Diltiazem Hcl166$8,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$482$157,302123 claims
AstraZenecaFarxiga$229$98,648110 claims
Boehringer IngelheimJardiance, Tradjenta$604$86,47467 claims
MerckJanuvia, Janumet Xr$100$52,09037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Rio Piedras

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →